

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Kaiser Permanente</p> <p>2. 2101 East Jefferson Street Rockville, MD 20852</p>	<p>In accordance with letter dated April 17, 2019.</p> <p>3. License number: 19-31420-017s amended in its entirety to read as follows:</p>	<p>4. Expiration Date: October 31, 2020</p> <p>5. Docket No.: 030-38361 Reference No.:</p>
--	--	--

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Iodine-131 permitted by 10 CFR 35.300	C. Any	C. 350 millicuries total	C. For any use permitted by 10 CFR 35.300 for which the patient can be released under the provisions of 10 CFR 35.75.

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located on the Ground Level of Capitol Hill Medical Center, 700 Second Street, NE, Washington, DC.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
19-31420-01

Docket or Reference Number
030-38361

Amendment No. 4

11. The Radiation Safety Officer for this license is Arnold Able.

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized Users

Material and Use

Carol P. Cardinale, M.D.

10 CFR 35.100, 10 CFR 35.200

Vincent Q. Dam, M.D.

Oral administration of sodium iodide I-131.

Howard DiPiazza, M.D.

10 CFR 35.100, 10 CFR 35.200

Yaning Liu, M.D.

10 CFR 35.100, 10 CFR 35.200

Philipose G. Mulugeta, M.D.

10 CFR 35.100, 10 CFR 35.200; Oral administration of sodium iodide I-131

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
19-31420-01Docket or Reference Number
030-38361

Amendment No. 4

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated August 31, 2010 [ML102500120]

B. Letter dated October 7, 2010 [ML102800451]

C. Letter dated February 24, 2017 [ML17065A265]

Date: July 26, 2019

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

By: 

Penny Lanzisera
Region 1